{"name":"Dong-A ST Co., Ltd.","slug":"dong-a-st-co-ltd","ticker":"","exchange":"","domain":"dongast.com","description":"","hq":"Seoul","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":52,"colorKey":"oncology","drugs":[{"name":"DA-4001 L","genericName":"DA-4001 L","slug":"da-4001-l","indication":"Other","status":"phase_1"},{"name":"DA-5221_01","genericName":"DA-5221_01","slug":"da-5221-01","indication":"Other","status":"phase_1"},{"name":"DA-2811","genericName":"DA-2811","slug":"da-2811","indication":"Other","status":"marketed"},{"name":"DA-3801 Injection","genericName":"DA-3801 Injection","slug":"da-3801-injection","indication":"Growth hormone deficiency (in development)","status":"phase_3"},{"name":"DA-4505","genericName":"DA-4505","slug":"da-4505","indication":"Other","status":"phase_1"},{"name":"Imatinib mesylate tablet 400 mg, 1 Tablet","genericName":"Imatinib mesylate tablet 400 mg, 1 Tablet","slug":"imatinib-mesylate-tablet-400-mg-1-tablet","indication":"Other","status":"phase_1"},{"name":"CELBESTA®","genericName":"CELBESTA®","slug":"celbesta","indication":"Other","status":"marketed"},{"name":"DA-2802","genericName":"DA-2802","slug":"da-2802","indication":"Menopausal vasomotor symptoms (hot flashes and night sweats)","status":"phase_3"},{"name":"DA-2803","genericName":"DA-2803","slug":"da-2803","indication":"Other","status":"marketed"},{"name":"DA-2803-R","genericName":"DA-2803-R","slug":"da-2803-r","indication":"Other","status":"marketed"},{"name":"DA-2902","genericName":"DA-2902","slug":"da-2902","indication":"Other","status":"phase_1"},{"name":"DA-2902-R","genericName":"DA-2902-R","slug":"da-2902-r","indication":"Other","status":"phase_1"},{"name":"DA-3501","genericName":"DA-3501","slug":"da-3501","indication":"Other","status":"phase_1"},{"name":"DA-4001C","genericName":"DA-4001C","slug":"da-4001c","indication":"Other","status":"phase_1"},{"name":"DA-5207","genericName":"DA-5207","slug":"da-5207","indication":"Other","status":"phase_1"},{"name":"DA-5207 B","genericName":"DA-5207 B","slug":"da-5207-b","indication":"Other","status":"phase_1"},{"name":"DA-5215 Tab","genericName":"DA-5215 Tab","slug":"da-5215-tab","indication":"Other","status":"phase_1"},{"name":"DA-5216-R","genericName":"DA-5216-R","slug":"da-5216-r","indication":"Other","status":"phase_1"},{"name":"DA-5222","genericName":"DA-5222","slug":"da-5222","indication":"Other","status":"phase_1"},{"name":"DA-5222-R2","genericName":"DA-5222-R2","slug":"da-5222-r2","indication":"Other","status":"phase_1"},{"name":"DA-7218","genericName":"DA-7218","slug":"da-7218","indication":"Other","status":"phase_1"},{"name":"DA3880","genericName":"DA3880","slug":"da3880","indication":"Other","status":"phase_1"},{"name":"DA5221-T1","genericName":"DA5221-T1","slug":"da5221-t1","indication":"Other","status":"phase_3"},{"name":"Placebo of DA-2803","genericName":"Placebo of DA-2803","slug":"placebo-of-da-2803","indication":"Other","status":"marketed"},{"name":"Placebo of DA-2803-R","genericName":"Placebo of DA-2803-R","slug":"placebo-of-da-2803-r","indication":"Other","status":"marketed"},{"name":"DA-1229_01","genericName":"DA-1229_01","slug":"da-1229-01","indication":"Other","status":"phase_1"},{"name":"DA-1229_01 fast","genericName":"DA-1229_01 fast","slug":"da-1229-01-fast","indication":"Other","status":"phase_1"},{"name":"DA-1229_01-R","genericName":"DA-1229_01-R","slug":"da-1229-01-r","indication":"Other","status":"phase_1"},{"name":"DA-1241","genericName":"DA-1241","slug":"da-1241","indication":"Other","status":"phase_2"},{"name":"DA-2811-C","genericName":"DA-2811-C","slug":"da-2811-c","indication":"Other","status":"phase_2"},{"name":"DA-4001 H","genericName":"DA-4001 H","slug":"da-4001-h","indication":"Other","status":"phase_1"},{"name":"DA-5213 10mg","genericName":"DA-5213 10mg","slug":"da-5213-10mg","indication":"Other","status":"phase_1"},{"name":"DA-5215-R Tab","genericName":"DA-5215-R Tab","slug":"da-5215-r-tab","indication":"Other","status":"phase_1"},{"name":"DA-5218","genericName":"DA-5218","slug":"da-5218","indication":"Other","status":"marketed"},{"name":"DA-5218-C","genericName":"DA-5218-C","slug":"da-5218-c","indication":"Other","status":"marketed"},{"name":"DA-5219","genericName":"DA-5219","slug":"da-5219","indication":"Functional dyspepsia","status":"phase_3"},{"name":"DA-5222-R1","genericName":"DA-5222-R1","slug":"da-5222-r1","indication":"Other","status":"phase_1"},{"name":"DA-5223","genericName":"DA-5223","slug":"da-5223","indication":"Other","status":"phase_1"},{"name":"DA-5223-R","genericName":"DA-5223-R","slug":"da-5223-r","indication":"Other","status":"phase_1"},{"name":"DA-6034 3%","genericName":"DA-6034 3%","slug":"da-6034-3","indication":"Other","status":"phase_2"},{"name":"DA-7503 Single dose","genericName":"DA-7503 Single dose","slug":"da-7503-single-dose","indication":"Other","status":"phase_1"},{"name":"DA5221-B1","genericName":"DA5221-B1","slug":"da5221-b1","indication":"Other","status":"phase_3"},{"name":"Metformin and Evogliptin","genericName":"Metformin and Evogliptin","slug":"metformin-and-evogliptin","indication":"Other","status":"phase_2"},{"name":"Motilitone® and Pantoline®","genericName":"Motilitone® and Pantoline®","slug":"motilitone-and-pantoline","indication":"Functional dyspepsia","status":"marketed"},{"name":"Pantoline®","genericName":"Pantoline®","slug":"pantoline","indication":"Other","status":"marketed"},{"name":"Placebo of Acetyl-L-Carnitine","genericName":"Placebo of Acetyl-L-Carnitine","slug":"placebo-of-acetyl-l-carnitine","indication":"Other","status":"marketed"},{"name":"Second period TWLO","genericName":"Second period TWLO","slug":"second-period-twlo","indication":"Other","status":"phase_1"},{"name":"Second period TWLO_C","genericName":"Second period TWLO_C","slug":"second-period-twlo-c","indication":"Other","status":"phase_1"},{"name":"Stillen","genericName":"Stillen","slug":"stillen","indication":"Other","status":"marketed"},{"name":"Stillen Tab.","genericName":"Stillen Tab.","slug":"stillen-tab","indication":"Pancreatic insufficiency","status":"marketed"},{"name":"Undiluted Intravenous DA-5217","genericName":"Undiluted Intravenous DA-5217","slug":"undiluted-intravenous-da-5217","indication":"Other","status":"phase_1"},{"name":"Vemlidy Tab","genericName":"Vemlidy Tab","slug":"vemlidy-tab","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"DA-6034","genericName":"DA-6034","slug":"da-6034","indication":"Dyslipidemia","status":"phase_3"},{"name":"DA-1229","genericName":"DA-1229","slug":"da-1229","indication":"Type 2 diabetes mellitus","status":"phase_2"},{"name":"DA5221-T2","genericName":"DA5221-T2","slug":"da5221-t2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DA-5212","genericName":"DA-5212","slug":"da-5212","indication":"Diabetic foot ulcers","status":"phase_3"},{"name":"DA5221-B2","genericName":"DA5221-B2","slug":"da5221-b2","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"DA-5212-R","genericName":"DA-5212-R","slug":"da-5212-r","indication":"Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions","status":"phase_3"},{"name":"Acetyl-L-Carnitine","genericName":"Acetyl-L-Carnitine","slug":"acetyl-l-carnitine","indication":"Age-related cognitive decline","status":"marketed"},{"name":"DMB-3115","genericName":"DMB-3115","slug":"dmb-3115","indication":"Schizophrenia","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"EPORON","genericName":"EPORON","slug":"eporon","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Leucostim 5µg/kg/day","genericName":"Leucostim 5µg/kg/day","slug":"leucostim-5-g-kg-day","indication":"Chemotherapy-induced neutropenia","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Baraclude Tab.®","genericName":"Baraclude Tab.®","slug":"baraclude-tab","indication":"Chronic hepatitis B infection in adults","status":"marketed"},{"name":"Jublia®","genericName":"Jublia®","slug":"jublia","indication":"Onychomycosis (fungal nail infection) caused by dermatophytes, non-dermatophyte molds, and yeasts","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"DA-3002","genericName":"DA-3002","slug":"da-3002","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women","status":"phase_3"},{"name":"Neupogen 5µg/kg/day","genericName":"Neupogen 5µg/kg/day","slug":"neupogen-5-g-kg-day","indication":"Chemotherapy-induced neutropenia (CIN) in cancer patients","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"DA-6034 5%","genericName":"DA-6034 5%","slug":"da-6034-5","indication":"Glaucoma","status":"phase_2"},{"name":"Rosuvastatin(Cresnon®)","genericName":"Rosuvastatin(Cresnon®)","slug":"rosuvastatin-cresnon","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Cytotec (reference drug)","genericName":"Cytotec (reference drug)","slug":"cytotec-reference-drug","indication":"Prevention of NSAID-induced gastric ulcers","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"NSAID (Aceclofenac)","genericName":"NSAID (Aceclofenac)","slug":"nsaid-aceclofenac","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"DA-4001 L","genericName":"DA-4001 L","slug":"da-4001-l","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5221_01","genericName":"DA-5221_01","slug":"da-5221-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-2811","genericName":"DA-2811","slug":"da-2811","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-3801 Injection","genericName":"DA-3801 Injection","slug":"da-3801-injection","phase":"phase_3","mechanism":"DA-3801 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.","indications":["Growth hormone deficiency (in development)"],"catalyst":""},{"name":"DA-4505","genericName":"DA-4505","slug":"da-4505","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-6034","genericName":"DA-6034","slug":"da-6034","phase":"phase_3","mechanism":"DA-6034 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) that enhances lipid metabolism and reduces inflammation.","indications":["Dyslipidemia","Metabolic syndrome"],"catalyst":""},{"name":"Imatinib mesylate tablet 400 mg, 1 Tablet","genericName":"Imatinib mesylate tablet 400 mg, 1 Tablet","slug":"imatinib-mesylate-tablet-400-mg-1-tablet","phase":"phase_1","mechanism":"Imatinib inhibits BCR-ABL tyrosine kinase and other kinases including KIT and PDGFR, blocking abnormal cell signaling that drives cancer growth.","indications":[],"catalyst":""},{"name":"CELBESTA®","genericName":"CELBESTA®","slug":"celbesta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-1229","genericName":"DA-1229","slug":"da-1229","phase":"phase_2","mechanism":"DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DA-2802","genericName":"DA-2802","slug":"da-2802","phase":"phase_3","mechanism":"DA-2802 is a selective activator of estrogen receptor beta (ERβ) that modulates estrogen signaling to treat menopausal symptoms and potentially other hormone-related conditions.","indications":["Menopausal vasomotor symptoms (hot flashes and night sweats)"],"catalyst":""},{"name":"DA-2803","genericName":"DA-2803","slug":"da-2803","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-2803-R","genericName":"DA-2803-R","slug":"da-2803-r","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-2902","genericName":"DA-2902","slug":"da-2902","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-2902-R","genericName":"DA-2902-R","slug":"da-2902-r","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-3501","genericName":"DA-3501","slug":"da-3501","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-4001C","genericName":"DA-4001C","slug":"da-4001c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5207","genericName":"DA-5207","slug":"da-5207","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5207 B","genericName":"DA-5207 B","slug":"da-5207-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5212-R","genericName":"DA-5212-R","slug":"da-5212-r","phase":"phase_3","mechanism":"DA-5212-R is a small molecule that modulates dopamine and serotonin pathways to treat cognitive and neuropsychiatric symptoms.","indications":["Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions","Neuropsychiatric symptoms in cognitive disorders"],"catalyst":""},{"name":"DA-5215 Tab","genericName":"DA-5215 Tab","slug":"da-5215-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5216-R","genericName":"DA-5216-R","slug":"da-5216-r","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5222","genericName":"DA-5222","slug":"da-5222","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5222-R2","genericName":"DA-5222-R2","slug":"da-5222-r2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-7218","genericName":"DA-7218","slug":"da-7218","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA3880","genericName":"DA3880","slug":"da3880","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA5221-T1","genericName":"DA5221-T1","slug":"da5221-t1","phase":"phase_3","mechanism":"DA5221-T1 is a therapeutic agent in phase 3 development by Dong-A ST Co., Ltd., but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"DA5221-T2","genericName":"DA5221-T2","slug":"da5221-t2","phase":"phase_3","mechanism":"DA5221-T2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"EPORON","genericName":"EPORON","slug":"eporon","phase":"phase_3","mechanism":"EPORON is an erythropoietin (EPO) receptor agonist that stimulates red blood cell production to treat anemia.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia"],"catalyst":""},{"name":"Placebo of DA-2803","genericName":"Placebo of DA-2803","slug":"placebo-of-da-2803","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo of DA-2803-R","genericName":"Placebo of DA-2803-R","slug":"placebo-of-da-2803-r","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Acetyl-L-Carnitine","genericName":"Acetyl-L-Carnitine","slug":"acetyl-l-carnitine","phase":"marketed","mechanism":"Acetyl-L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production.","indications":["Age-related cognitive decline","Mild cognitive impairment","Peripheral neuropathy","Fatigue and energy metabolism disorders"],"catalyst":""},{"name":"Baraclude Tab.®","genericName":"Baraclude Tab.®","slug":"baraclude-tab","phase":"marketed","mechanism":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.","indications":["Chronic hepatitis B infection in adults","Chronic hepatitis B infection in children and adolescents"],"catalyst":""},{"name":"Cytotec (reference drug)","genericName":"Cytotec (reference drug)","slug":"cytotec-reference-drug","phase":"marketed","mechanism":"Cytotec (misoprostol) is a prostaglandin E1 analog that reduces gastric acid secretion and protects the gastric mucosa.","indications":["Prevention of NSAID-induced gastric ulcers","Treatment of gastric ulcers"],"catalyst":""},{"name":"DA-1229_01","genericName":"DA-1229_01","slug":"da-1229-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-1229_01 fast","genericName":"DA-1229_01 fast","slug":"da-1229-01-fast","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-1229_01-R","genericName":"DA-1229_01-R","slug":"da-1229-01-r","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-1241","genericName":"DA-1241","slug":"da-1241","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-2811-C","genericName":"DA-2811-C","slug":"da-2811-c","phase":"phase_2","mechanism":"DA-2811-C is a small molecule inhibitor targeting a specific cellular pathway involved in disease pathogenesis.","indications":[],"catalyst":""},{"name":"DA-3002","genericName":"DA-3002","slug":"da-3002","phase":"phase_3","mechanism":"DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women"],"catalyst":""},{"name":"DA-4001 H","genericName":"DA-4001 H","slug":"da-4001-h","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5212","genericName":"DA-5212","slug":"da-5212","phase":"phase_3","mechanism":"DA-5212 is a selective inhibitor of phosphodiesterase 5 (PDE5) that enhances nitric oxide signaling to improve blood flow and tissue perfusion.","indications":["Diabetic foot ulcers","Chronic wounds and tissue regeneration"],"catalyst":""},{"name":"DA-5213 10mg","genericName":"DA-5213 10mg","slug":"da-5213-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5215-R Tab","genericName":"DA-5215-R Tab","slug":"da-5215-r-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5218","genericName":"DA-5218","slug":"da-5218","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5218-C","genericName":"DA-5218-C","slug":"da-5218-c","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5219","genericName":"DA-5219","slug":"da-5219","phase":"phase_3","mechanism":"DA-5219 is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying.","indications":["Functional dyspepsia","Gastroparesis"],"catalyst":""},{"name":"DA-5222-R1","genericName":"DA-5222-R1","slug":"da-5222-r1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5223","genericName":"DA-5223","slug":"da-5223","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5223-R","genericName":"DA-5223-R","slug":"da-5223-r","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-6034 3%","genericName":"DA-6034 3%","slug":"da-6034-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-6034 5%","genericName":"DA-6034 5%","slug":"da-6034-5","phase":"phase_2","mechanism":"DA-6034 is a topical ophthalmic agent that reduces intraocular pressure and promotes aqueous humor outflow.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"DA-7503 Single dose","genericName":"DA-7503 Single dose","slug":"da-7503-single-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA5221-B1","genericName":"DA5221-B1","slug":"da5221-b1","phase":"phase_3","mechanism":"DA5221-B1 is a therapeutic candidate in phase 3 development by Dong-A ST Co., Ltd., but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"DA5221-B2","genericName":"DA5221-B2","slug":"da5221-b2","phase":"phase_3","mechanism":"DA5221-B2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"DMB-3115","genericName":"DMB-3115","slug":"dmb-3115","phase":"phase_3","mechanism":"DMB-3115 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.","indications":["Schizophrenia"],"catalyst":""},{"name":"Jublia®","genericName":"Jublia®","slug":"jublia","phase":"marketed","mechanism":"Jublia is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Onychomycosis (fungal nail infection) caused by dermatophytes, non-dermatophyte molds, and yeasts"],"catalyst":""},{"name":"Leucostim 5µg/kg/day","genericName":"Leucostim 5µg/kg/day","slug":"leucostim-5-g-kg-day","phase":"phase_3","mechanism":"Leucostim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.","indications":["Chemotherapy-induced neutropenia","Severe chronic neutropenia","Mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation"],"catalyst":""},{"name":"Metformin and Evogliptin","genericName":"Metformin and Evogliptin","slug":"metformin-and-evogliptin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Motilitone® and Pantoline®","genericName":"Motilitone® and Pantoline®","slug":"motilitone-and-pantoline","phase":"marketed","mechanism":"Motilitone enhances gastric muscle contractions and accelerates gastric emptying by acting as a dopamine antagonist and acetylcholinesterase inhibitor.","indications":["Functional dyspepsia","Gastroesophageal reflux disease (GERD)","Postoperative gastric stasis"],"catalyst":""},{"name":"NSAID (Aceclofenac)","genericName":"NSAID (Aceclofenac)","slug":"nsaid-aceclofenac","phase":"marketed","mechanism":"Aceclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Rheumatoid arthritis","Osteoarthritis","Ankylosing spondylitis","Acute pain and inflammation"],"catalyst":""},{"name":"Neupogen 5µg/kg/day","genericName":"Neupogen 5µg/kg/day","slug":"neupogen-5-g-kg-day","phase":"phase_3","mechanism":"Neupogen (filgrastim) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts to prevent or treat infections in immunocompromised patients.","indications":["Chemotherapy-induced neutropenia (CIN) in cancer patients","Severe chronic neutropenia","Peripheral blood progenitor cell (PBPC) mobilization for autologous transplantation"],"catalyst":""},{"name":"Pantoline®","genericName":"Pantoline®","slug":"pantoline","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of Acetyl-L-Carnitine","genericName":"Placebo of Acetyl-L-Carnitine","slug":"placebo-of-acetyl-l-carnitine","phase":"marketed","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Rosuvastatin(Cresnon®)","genericName":"Rosuvastatin(Cresnon®)","slug":"rosuvastatin-cresnon","phase":"marketed","mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia","Primary prevention of cardiovascular disease in at-risk patients","Secondary prevention of cardiovascular events in patients with established coronary artery disease"],"catalyst":""},{"name":"Second period TWLO","genericName":"Second period TWLO","slug":"second-period-twlo","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Second period TWLO_C","genericName":"Second period TWLO_C","slug":"second-period-twlo-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Stillen","genericName":"Stillen","slug":"stillen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Stillen Tab.","genericName":"Stillen Tab.","slug":"stillen-tab","phase":"marketed","mechanism":"Stillen is a digestive enzyme preparation that aids in the breakdown and absorption of nutrients in the gastrointestinal tract.","indications":["Pancreatic insufficiency","Digestive disorders requiring enzyme supplementation"],"catalyst":""},{"name":"Undiluted Intravenous DA-5217","genericName":"Undiluted Intravenous DA-5217","slug":"undiluted-intravenous-da-5217","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vemlidy Tab","genericName":"Vemlidy Tab","slug":"vemlidy-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNYk5fUTdiZXJyZXNiS3ZQc1ZYRldqQ1BKQ2tEcVdqRlZ1U0o2dzNLSEwyU2o3czBDVnpKWC1aYnFJMVNUZ0hDZFRpS2trZGpzUGRJcXltYXoxYWdaLXhzems0VG1ObS1sRzdmUmJ1OFpnSHVwcXpCQXlvdVcxcjJOTWlVTHllcFZRWWItWGJneXI3cGdVb3lXS0RRRktkS0xYMGNqcTY2eXRWTHBTM0NrTGJvRjN6a2ctZWlKTzQyZFZMNWlTWDU1SzZINjh4bVdOVkUxMHhhSjAzX2QxZWMxUDM3MUxSbXVmdkJ2aFhZWGRKbU5IR19kVTN2WVJOSTZkOHpRWWdoVnFFTnNhaGc?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Trea","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-28","type":"pipeline","source":"simplywall.st","summary":"Subdued Growth No Barrier To Dong-A ST Co., Ltd.'s (KRX:170900) Price - simplywall.st","headline":"Subdued Growth No Barrier To Dong-A ST Co., Ltd.'s (KRX:170900) Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5tbkQ1X215c0xSTnZUcEpQcHRlNS1tSUZTUDJkU09JZklIS0ViRDllblJZeUIxSjNXcG5kTVdvM2U4cTZ5ZmEzd1pOVElXQzVUd0JCQ1lEaHNDcmI5VWo1ZnF2ZVZpblMydGk4OEZ30gFyQVVfeXFMUFJZXzhwQVB4U3J4V21QdlhPNElZUTVJdmIxQTZ3ZXNtZDdfU0pGaU5icDQwbTVYSlA2TmJZUldRZzFoWWZiT3dOWGtxeDhnUUM2WWVOY3BmclBZLTc0SDJaZ2ZMQXBONXoyS0M2aXBFSjBR?oc=5","date":"2025-11-28","type":"pipeline","source":"koreabiomed.com","summary":"Dong-A ST launches new benign prostatic hyperplasia treatment - koreabiomed.com","headline":"Dong-A ST launches new benign prostatic hyperplasia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5oQ0pfX2dNLUNtQWhCWlpRYUdpQmUxWnAtQ2F2UnRpSWU1SEMzSzBPYUpUWVpaYXdjYTRzZ2dSM0hJN3U0Tk1hc3BZTHZ0N01YWFlnTF9DbnhfemI0cHdsRHBZWnRnOENLZjg1RkxB0gFyQVVfeXFMT0lVejhsTHlmWm9rZ3dQb1NTUkY2QUFMc2JnZTdGYjkxWVJLbDJkd3EwUkRXN1Q3NzVzaVhBQ1J5SF8ybm4yY1JyN24wb2pWY2JoVmtVNkI4RkhTY0xnZG9RQjJxcGNrZXVadlVJSnV3ajd3?oc=5","date":"2025-08-26","type":"pipeline","source":"koreabiomed.com","summary":"Dong-A ST speeds up developing new drugs utilizing AI - koreabiomed.com","headline":"Dong-A ST speeds up developing new drugs utilizing AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBKOHRFZmp5bXFoRnZtdTJkbGwwaTVMNnp6RnBtYzV2SFBETW8xQ3d2eXZldTg4R2puaGxlRU9hc1lqYVVrdlg4TGJ2cnJtMlJoMktkUVFsNGplNFhySGNR?oc=5","date":"2025-08-19","type":"patent","source":"동아비즈니스리뷰 | DBR","summary":"Dong-A ST Launches Stelara Biosimilar in U.S. - 동아비즈니스리뷰 | DBR","headline":"Dong-A ST Launches Stelara Biosimilar in U.S. - 동아비즈니스리뷰 | DBR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSGVkVTBnaUhxb3FPU1Rocy1DWm45SGJWeWEzNlh2UUhVaUdTMkhPU0U5LTd4Nkl0QWc0Qm1scFgzczlNNWNEM0pGTTVaandhVm9hVXkyT1JYTllMNGdkVGFYaDl3a0RaT1daT2ptZzZxRkpEak9QVWd2dVoyYXpWQy1xakNiREN5OGdhRElCUmxiUVY4ZFZzVlFaXzJFZ05GZjdlbTBpelhSSE0?oc=5","date":"2024-12-19","type":"regulatory","source":"BioSpace","summary":"Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - BioSpace","headline":"Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOY3lkdjYzelllOHFqcS1ENjV2RGJaTng1SVJ5ZjRsM3I1QkZiTTFNLUt3MG12dFBlSy12blhDRXpGNGNnbHBoZ3lsWGhsS2FZS2pCeXA0OVVzYkgtSlhYZUlTTTZIRVptZ2xRYVRaVk5iRnEyZGt3XzRPb29wY215VEFpVENLZ3JjUDFxcXRwMXEyX1ZiR3dNdjBSQjQ5aVBvOTZ3?oc=5","date":"2024-11-22","type":"regulatory","source":"BioWorld News","summary":"Two Stelara biosimilars among 15 US FDA approvals in October - BioWorld News","headline":"Two Stelara biosimilars among 15 US FDA approvals in October","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPY0VEVkNScjhZRGFDRHp1Q1Izd19vV1kteHdiZlZDYjZrQlJKa1ZZZkszdFdRZHQtQVdyaUpXSHZlZzJ6WHc4bkliODg2UlZHRUFrWEV1REZ2U3ZVS1lqMmRDcTFEOGs5QnVZeG1nTHUtLUdiWkVTQl9Ob2l1VWVwZXRDejE4U0FDal9PZlNsZVVqNFpnNHZlTVRucEtPbER2d3NzU25UNFhjV0dmRUwtOVp2LXY4Zw?oc=5","date":"2024-10-21","type":"regulatory","source":"BioSpace","summary":"CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara® - BioSpace","headline":"CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPV3dIN2F0dDdTb3ljZTNSMnFoZ0VDNGgzbFJrSU1LRVgzZmx1dVFZcFFLbUIxaTJHVjJwa2FualVLVEdUbjI1Zm5fRFdQXzZMNS00eGNBTDV0ZGplTlhZdUJTZUllZDBPSEVHaEZyZFVpQzNITnRqcE51RmI0cG51eTBIY2txMlZYZ1F5NVZXcURIX19leEZzM3VDMWtPTVA4eVpHRVdJS3hYNkU1LXpqS3RJUm0tWE5xMm5XTzl2ajZ4OG9iUjBkUU5SeDZyUQ?oc=5","date":"2024-10-11","type":"regulatory","source":"Business Wire","summary":"US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Business Wire","headline":"US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQcTF2VnliUm5rU0dxZ2tMUEZxTTJTaGVpaGw3SDEySF92TWlHZktUVkVjNWhlS1FuX1BqVUtXTWpISXhiNEE5ckN6RkwzZnpuV2dyYWtiYkdfeEZuUWlCMXNsZjhkcTFmQzU2TWsxZTlZaUpjdWNjUVJGVjk3XzhDZy0ySGVuQ2k5ODgwU0xIbkxLcVVWT2NLdVdvcFM5ZVU?oc=5","date":"2024-06-10","type":"pipeline","source":"BioWorld News","summary":"Abtis tapping ADC market with Claudin18.2-targeting AT-211 - BioWorld News","headline":"Abtis tapping ADC market with Claudin18.2-targeting AT-211","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1fNDIzNG44cjctYzAxWFdCWlRCblZFMmtrOTFmSlZvR2N0bTloRjVWUEROdTA2YWR1dFZOaVpWUk90V0lRUW9hZnI2Wi1tbGRvTWxMM3AtZXBkOWhvSExkRFVpWmI1b2ZIS3hGWEx3?oc=5","date":"2024-05-07","type":"regulatory","source":"KED Global","summary":"S.Korean anti-obesity drugmakers eye niche demand - KED Global","headline":"S.Korean anti-obesity drugmakers eye niche demand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA4ZGpIYlJuNllWY0Z5SGgtM19NeUdCYmRiMFU3NFp0VXJjUzdoaGNOZjBTbDVrSmQxdnJ2YlJWTl9YQnlKQzJTSW9jMkw0ODMxQXZtbHE1eFhvUnFGaTYtbGR3cUo3Qk9IcFNQZFBR?oc=5","date":"2024-01-04","type":"deal","source":"KED Global","summary":"SK Biopharm, Dong-A ST sign licensing deal of Cenobamate - KED Global","headline":"SK Biopharm, Dong-A ST sign licensing deal of Cenobamate","sentiment":"neutral"}],"patents":[],"drugCount":70,"phaseCounts":{"phase_1":30,"marketed":19,"phase_3":15,"phase_2":6},"enrichmentLevel":0,"visitCount":10,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}